NewAmsterdam Pharma Company N.V. (NAMS)
NAMS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$20.19
-4.99% on the day
Market cap
$2.4B
Mid cap
Revenue · 2025
$22.5M
-50.6% on 2024
Net income · 2025
-$203.0M
-902.1% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | NAMS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Netherlands |
| IPO year | Not reported by the screener |
| SEC CIK | 0001936258 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | P7 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $22.5M |
| Net income | -$203.0M |
| Operating income | -$225.7M |
| Net margin | -902.1% |
| Operating margin | -1002.9% |
| Revenue growth | -50.6% |
| Cash | $490.0M |
| Total assets | $769.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 107.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-03-10 |
| Latest annual report | 10-K | 2026-02-18 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-09-29 |
| Latest proxy | DEF 14A | 2026-05-06 |
Source: SEC EDGAR submissions feed, 412 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.4% |
| 1 month | -7.3% |
| 3 months | -36.8% |
| Year to date | -44.1% |
| 1 year | -47.2% |
| From 52-week high | -52.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| NAMSW | NewAmsterdam Pharma Company N.V. Warrant | $10.95 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LQDA | Liquidia Corporation | $26.81 | -3.11% | $2.4B |
| SUPN | Supernus Pharmaceuticals Inc. | $42.01 | -1.87% | $2.4B |
| MBX | MBX Biosciences Inc. | $49.00 | -5.80% | $2.4B |
| HCM | HUTCHMED (China) Limited | $13.50 | -1.32% | $2.4B |
| SLS | SELLAS Life Sciences Group Inc. | $12.41 | +4.02% | $2.5B |
| VCRE | Vicore Pharma Holding AB | $8.95 | -3.03% | $2.5B |
| PBH | Prestige Consumer Healthcare Inc. | $48.50 | -1.02% | $2.3B |
| NRIX | Nurix Therapeutics Inc. | $22.13 | -0.14% | $2.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier